The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Unattributed | Alive

Total Raised


Last Raised

$2.61M | 2 yrs ago

About Lipella Pharmaceuticals

Lipella Pharmaceuticals is a specialty biopharmaceutical company focused on the development and commercialization of novel liposome formulations for multiple therapeutic applications. Lipellas research and development assets include experimental and clinical stage products for interstitial cystitis, overactive bladder, and hemorrhagic cystitis. Lipella is a privately held company based in Pittsburgh, PA.

Lipella Pharmaceuticals Headquarter Location

5414 Guarino Road

Pittsburgh, Pennsylvania, 15217,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Lipella Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Lipella Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Lipella Pharmaceuticals Patents

Lipella Pharmaceuticals has filed 7 patents.

The 3 most popular patent topics include:

  • Cardiac anatomy
  • Cardiology
  • Chronic pain syndromes
patents chart

Application Date

Grant Date


Related Topics




Drug delivery devices, Dosage forms, Rare diseases, Membrane biology, Autosomal recessive disorders


Application Date


Grant Date



Related Topics

Drug delivery devices, Dosage forms, Rare diseases, Membrane biology, Autosomal recessive disorders



Latest Lipella Pharmaceuticals News

Global Interstitial Cystitis Market 2020:Trends,Outlook,Future Prospects,Growth Insights,Forecast To 2027||Players- Mylan N.V., Johnson & Johnson Services Inc, Astellas Pharma Inc, Lipella Pharmaceuticals Inc, Grünenthal, Liminal BioSciences Inc, Neoleukin Therapeutics, Inc

Jan 28, 2021

||Players- Mylan N.V., Johnson & Johnson Services Inc, Astellas Pharma Inc, Lipella Pharmaceuticals Inc, Grünenthal, Liminal BioSciences Inc, Neoleukin Therapeutics, Inc Present  “ Global Interstitial cystitis Market – Industry Trends and Forecast to 2027” new report to its research database. The report spread No of pages: 350 No of Figures: 60 No of Tables: 220 in it. The interstitial cystitis market research report is extremely significant for the success of business endeavors. It helps to set achievable targets for business growth, sales, and the latest product developments. Moreover, the report aids in making well-informed market decisions about the services and develop effective strategies. With this report, it gets easy to pinpoint problems in the existing business model and meet the needs of customers and evaluate the success. With the use of reports, businesses can understand the preferences, buying patterns, and needs of the customers. The Interstitial cystitis business report guides to increase profits and beat business rivals. Global interstitial cystitis market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing at a healthy CAGR in the above-mentioned research forecast period. Get Free Full PDF Sample Copy of Report (Including Full TOC, List of Tables & Figures, Chart) @ Key Market Competitors Covered in the Report Mylan N.V. Patient Epidemiology Analysis Interstitial cystitis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period. According to Data Bridge Market Research, the market for interstitial cystitis market is accelerating because of the rising cases of interstitial cystitis and  bladder trauma  or overstretching. Additionally, increase in research and development activities, advancements in the technology and adoption of sedentary life-style positively affect the interstitial cystitis market. Furthermore, technological advancement and product innovations extend profitable opportunities to the interstitial cystitis market players. Now the question is which are the other regions that interstitial cystitis market is targeting? Data Bridge Market Research has estimated a large growth in North America because of the involvement of prominent players in the research and development activities and availability of sophisticated treatment options. Europe is considered as the second largest market because of the high cases of interstitial cystitis. Asia-Pacific is expected to witness significant growth due to the large number of generic manufacturers, developing healthcare facilities and rise in government initiatives and specialist communities in the region. To Understand How Covid-19 Impact Is Covered In This Report, Get Free Covid-19 Sample @ Global Interstitial Cystitis Market Scope and Market Size Interstitial cystitis market is segmented on the basis of drugs, route of administration, end-users and distribution channel. Based on drugs, the global interstitial cystitis market is segmented into pentosan polysulfate sodium, dimethyl sulfoxide and others. Route of administration segment for global interstitial cystitis market is categorized into oral, intravesical and others On the basis of end-users, the global interstitial cystitis market is segmented into hospitals, homecare, specialty clinics and others. On the basis of distribution channel, the global interstitial cystitis market has been bifurcated into hospital pharmacy, online pharmacy and retail pharmacy. There Are 15 Chapters To Display The Global Interstitial Cystitis Market Chapter 1, Definition, Specifications and Classification of Interstitial cystitis, Applications of Interstitial cystitis, Market Segment by Regions; Chapter 2, Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure; Chapter 3, Technical Data and Manufacturing Plants Analysis of Interstitial cystitis, Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis; Chapter 4, Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment); Chapter 5 and 6, Regional Market Analysis that includes United States, China, Europe, Japan, Korea & Taiwan, Interstitial cystitis Segment Market Analysis (by Type); Chapter 7 and 8, The Interstitial cystitis Segment Market Analysis (by Application) Major Manufacturers Analysis of Interstitial cystitis Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type Invasive Interstitial cystitis, Non-Invasive Interstitial cystitis, Market Trend by Application; Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis; Chapter 11, The Consumers Analysis of Global Interstitial cystitis; Chapter 12, Interstitial cystitis Research Findings and Conclusion, Appendix, methodology and data source; Chapter 13, 14 and 15, Interstitial cystitis sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source. Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart) @ Key Focus Of The Report This report provides pin-point analysis for changing competitive dynamics It provides a forward-looking perspective on different factors driving or restraining market growth It provides five-year forecast assessed on the basis of how the market is predicted to grow It helps in understanding the key product segments and their future It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments Queries Related To The Interstitial Cystitis Market: Which application segments will perform better and achieve success in worldwide through the forecast years? What are the key factors driving the market growth? Who are the key vendors in this Industry? Which are the impressive business sectors where best players want their own expansion in future? What are the market dynamics? What are the limits ruining the development rate? What is the focused circumstance to advance development? What are the opportunities and threats faced by the performers in the global market? What are the development rates for this Industry? About Us: Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get Customization and Discount on Report by emailing  . We are content with our glorious 99.9 % client satisfying rate. Contact:

Lipella Pharmaceuticals Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Lipella Pharmaceuticals Rank

  • Where is Lipella Pharmaceuticals's headquarters?

    Lipella Pharmaceuticals's headquarters is located at 5414 Guarino Road, Pittsburgh.

  • What is Lipella Pharmaceuticals's latest funding round?

    Lipella Pharmaceuticals's latest funding round is Unattributed.

  • How much did Lipella Pharmaceuticals raise?

    Lipella Pharmaceuticals raised a total of $2.97M.

  • Who are the investors of Lipella Pharmaceuticals?

    Investors of Lipella Pharmaceuticals include National Institutes of Health and Pittsburgh Life Sciences Greenhouse.

  • Who are Lipella Pharmaceuticals's competitors?

    Competitors of Lipella Pharmaceuticals include Longevica, Cyclacel Pharmaceuticals, GangaGen, ADV Bioscience, Telormedix and 11 more.

You May Also Like


ParentPlus LLC was formed to alleviate male-factor subfertility by bringing biotechnology to millions of subfertile couples for whom intra-uterine insemination (IUI) might be an appropriate therapy. This therapy, with spousal or donor sperm, is underutilized perhaps in part because it frequently is neglected in the popular press. It is the company's belief that sperm from many subfertile men should be the target of a therapy based on modern biotechnology. Successful application of this concept could allow far more subfertile couples, when male-factor subfertility is a problem, to use IUI with spousal sperm to fulfill their dream of a having a baby. Hence, the focus of ParentPlus LLC is on reproductive media to enhance success primarily via IUI, but also enhancing IVF. In due course, demonstrated increased success rate with IUI using ParentPlus products will increase acceptance of IUI as the low cost alternative to highly publicized expensive treatments.

Biosceptre International

Biosceptre has identified a pan-cancer target, present in many cancer types, and importantly not found in healthy tissue. Early research and initial evidence suggest that drugs directed at the nf-P2X7 target have the potential to redefine cancer therapy. The Company has raised AUD33m and will be raising further capital through both existing and new investors. Biosceptre has a rigorous, international patent portfolio extending to 2032, providing broad protection of the target and specific protection of antibody products. The Company is developing therapeutics and diagnostics to bind nf-P2X7, with the core of product development in topical and systemic cancer drugs. Biosceptreis also developing an immuno-oncology vaccine, through an existing collaboration, and is in discussions with developmental partners to develop diagnostic and imaging technologies to detect and monitor cancer. Biosceptre is supported by a world-class scientific advisory board, the members of which have been central in the development of numerous, highly successful, biotechnology companies and products. The Company has the team, capital, and plan to create substantial value from this unique, patent-protected, technology. The business is headquartered in Cambridge, UK with additional research facilities in Sydney, Australia.

Qwell Pharmaceuticals

Qwell Pharmaceuticals is a biotechnology company focused on small molecule development primarily for oncology indications.

Bolder BioTechnology

Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create human protein pharmaceuticals with enhanced therapeutic properties. Most protein pharmaceuticals are rapidly eliminated by the body, which limits their effectiveness and requires that they be administered by frequent, often daily, injection. The company's products are designed to last longer in the body, which aims to allow them to be administered less frequently, e.g., once per week to once per month, and maximizes their therapeutic benefits to patients. Company scientists combine protein structure/function information with targeted protein modification technologies to rationally design long-acting protein pharmaceuticals that, in many cases, are 10-100-fold more potent than competing products prepared using non-targeted protein modification technologies. Bolder BioTechnology has a robust pipeline of products in preclinical development, including products for the treatment of hematological and endocrine disorders, cancer and infectious disease. The company intend to commercialize these products independently and through strategic alliances with corporate partners.

BSA Ambiente S.r.l.

BSA Ambiente, founded in 1994, was born from an idea by Francesco Frerio: developing the application of technologies of natural origin (biotechnology) with low environmental impact to reclaim - at competitive costs - contaminated land and water environments. Since its early interventions, BSA Ambiente has always considered Research & Development as an issue of paramount importance for the development of new application scenarios valid and effective for its own solutions.nIn situ remediation of environmental failure is the priority of BSA Ambiente, coherently with the corporate mission: to facilitate the growth of an ecosustainable environment.nThe developed methodology aims to allow the restoration of the balanced ecological conditions prior to failure without generating, handling or producing any other waste.

Immunservice Logo

Immunservice is a biopharmaceutical company addressing orphan disease indications as well as large market indication areas, especially those of high unmet medical need.Immunservice's biomimetic approach translates human immune hormones into well tolerated and highly effective marketable drugs that improve survival and quality of life in patients.Biomimetic therapy has the clear potential to cure patients with cancer, even those who are in urgent need and have little or no treatment alternatives.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.